.png)
Portfolio
KMAK Capital is a family office focused on managing a diverse investment portfolio across various sectors. We identify strategic opportunities that align with our long-term vision and market trends, ensuring each investment meets our criteria for growth. Our robust portfolio reflects our commitment to innovation and value creation.
Biotech
Siren Biotechnology
Siren Biotechnology is a clinical-stage biotechnology company developing next-generation cancer therapies through its immuno-gene therapy platform. The company combines gene therapy with cytokine-based immunotherapy to activate the immune system directly within tumors, driving targeted and durable anti-tumor responses. Designed as a universal platform, Siren’s approach has the potential to be applied across multiple solid tumor types, with initial focus on high-grade gliomas.
Alaya.Bio
Alaya.Bio is a preclinical-stage biotechnology company developing next-generation CAR-T therapies using a proprietary polymeric nanoparticle delivery platform. The company’s approach enables in vivo genetic reprogramming of immune cells, eliminating the need for complex ex vivo manufacturing processes. By simplifying production and improving scalability, Alaya aims to expand access and effectiveness of advanced cell therapies.
Med Device
Avvio Medical
Avvio Medical is a clinical-stage medical technology company focused on advancing the treatment of kidney stone disease. The company is developing a novel, non-invasive ultrasound-based platform that uses microbubble-enhanced acoustic energy to break down stones without surgery or general anesthesia. By enabling faster, office-based procedures and improving patient outcomes, Avvio aims to expand access to care while reducing overall healthcare costs.
Healthcare Technology
Title21 Health Solutions
Title21 Health Solutions is a healthcare technology company providing enterprise software solutions for the cell and gene therapy industry. The company’s platform supports compliance, manufacturing, and quality management within highly regulated environments. By enabling scalable and compliant operations, Title21 plays a critical role in advancing the commercialization of complex biologic therapies.
Private Credit
Capital Fund II
Capital Fund II is a real estate credit investment vehicle focused on providing short-term, asset-backed loans to real estate investors and developers. The fund employs a disciplined, asset-based underwriting approach, prioritizing collateral quality and conservative loan-to-value ratios. With a diversified portfolio of first-lien loans across multiple markets, the strategy is designed to preserve investor capital while generating consistent income-driven returns.
Industrial
Finial Group
Finial Group is a real estate investment and development firm specializing in light industrial assets across high-growth markets. The firm focuses on acquiring and repositioning underutilized properties to meet increasing demand for functional, last-mile industrial space. Through a hands-on approach to asset management and development, Finial creates value by improving usability, occupancy, and long-term income durability.
Multi-Family
JT Capital
JT Capital Group is a real estate investment and development firm focused on multifamily and residential projects in high-growth markets. The firm emphasizes disciplined underwriting, efficient project execution, and market-driven design. Value is created through strategic development, operational oversight, and alignment with evolving housing demand.
ClearWorth Capital
ClearWorth Capital is a vertically integrated real estate investment firm focused on multifamily acquisitions and asset management. The firm targets properties in growth-oriented markets and applies operational expertise to drive performance improvements. Value is created through disciplined acquisitions, strategic renovations, and active management of leasing and operations.
MedCore
MedCore Partners is a real estate investment and development firm specializing in healthcare real estate. The firm focuses on medical office and outpatient facilities, partnering with leading healthcare providers to deliver purpose-built environments. By aligning real estate strategy with healthcare delivery trends, MedCore creates value through long-term tenant relationships and specialized asset expertise.